A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis

Trial Profile

A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Fluorine-18 ML 10 (Primary)
  • Indications Breast cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Small cell lung cancer
  • Focus Diagnostic use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Jun 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov record.
    • 07 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top